Silvia Mezi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9453513/publications.pdf

Version: 2024-02-01

567281 330143 1,509 43 15 37 citations h-index g-index papers 43 43 43 2698 all docs docs citations times ranked citing authors

#	Article	lF	CITATIONS
1	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	10.7	835
2	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol \tilde{A}^3 gica, 2012, 51, 873-879.	1.8	66
3	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. British Journal of Clinical Pharmacology, 2014, 77, 929-938.	2.4	65
4	Follow-up program in head and neck cancer. Critical Reviews in Oncology/Hematology, 2017, 113, 151-155.	4.4	49
5	Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 705096.	4.8	47
6	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines, 2020, 8, 203.	4.4	38
7	Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in human breast cancer cells. International Journal of Oncology, 2012, 41, 2128-2138.	3.3	36
8	Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer. Cancers, 2014, 6, 2187-2223.	3.7	34
9	Advances in the Management of HPV-Related Oropharyngeal Cancer. Journal of Oncology, 2019, 2019, 1-8.	1.3	34
10	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Frontiers in Immunology, 2020, 11, 1243.	4.8	30
11	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. Journal of Personalized Medicine, 2021, 11, 651.	2.5	28
12	Neuroendocrine tumors of the gallbladder: a case report and review of the literature. Journal of Medical Case Reports, 2011, 5, 334.	0.8	27
13	Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study. Applied Sciences (Switzerland), 2020, 10, 3896.	2.5	26
14	The role of opioids in cancer response to immunotherapy. Journal of Translational Medicine, 2021, 19, 119.	4.4	24
15	Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza―University of Rome Head and Neck Unit clinical recommendations. Critical Reviews in Oncology/Hematology, 2017, 120, 93-97.	4.4	17
16	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	3.7	15
17	Clinical significance of epithelial-to-mesenchymal transition in laryngeal carcinoma: Its role in the different subsites. Head and Neck, 2017, 39, 1806-1818.	2.0	15
18	The 5-Ws of immunotherapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2020, 153, 103041.	4.4	13

#	Article	IF	CITATIONS
19	Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. Acta Oncol $ ilde{A}^3$ gica, 2013, 52, 187-190.	1.8	12
20	Primary squamous cell carcinoma of major salivary gland: "Sapienza Head and Neck Unit―clinical recommendations. Rare Tumors, 2020, 12, 203636132097352.	0.6	12
21	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	2.8	12
22	Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 611-615.	1.3	11
23	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. Cancers, 2020, 12, 2648.	3.7	10
24	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines, 2020, 8, 191.	4.4	10
25	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. Cancers, 2021, 13, 1080.	3.7	10
26	In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. International Journal of Oncology, 2003, 22, 1233.	3.3	5
27	In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. International Journal of Oncology, 2003, 22, 1233-40.	3.3	4
28	Somatostatin receptor scintigraphy in metastatic breast cancer patients. Oncology Reports, 2005, 13, 31-5.	2.6	4
29	Sinonasal Undifferentiated Carcinoma in a Patient Previously Treated for an Intestinal-Type Adenocarcinoma: Metachronous Neoplasms or Recurrence of a Different Tumor Type?. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 1779-1781.	0.9	3
30	Aesthetic satisfaction in lip and palate clefts: a comparative study between secondary and tertiary bone grafting. Clinica Terapeutica, 2018, 169, e62-e66.	0.3	3
31	Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy. In Vivo, 2021, 35, 3355-3360.	1.3	3
32	A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: "Sapienza Head and Neck Unit―Proposal. International Journal of Environmental Research and Public Health, 2021, 18, 1851.	2.6	2
33	Implant placement in oral squamous cells carcinoma patients treated with chemoradiotherapy: "Sapienza Head and Neck Unit" clinical recommendations. European Review for Medical and Pharmacological Sciences, 2019, 23, 9923-9930.	0.7	2
34	Somatostatin receptor scintigraphy in metastatic breast cancer patients. Oncology Reports, 0, , .	2.6	2
35	Phase 2 of coronavirus disease (COVIDâ€19) and head and neck cancer: An action plan. Oral Diseases, 2022, 28, 970-972.	3.0	1
36	Efficacy and Tolerability of Selective Internal Radiotherapy With Yttrium-90 as Consolidation Treatment After Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, e272-e276.	2.3	1

3

#	Article	IF	CITATIONS
37	Management of a rare case of squamous cell carcinoma of the tongue in a patient affected by progeria. Oral Oncology, $2021, 113, 105032$.	1.5	1
38	Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. Journal of Translational Medicine, 2021, 19, 303.	4.4	1
39	Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience. Anti-Cancer Drugs, 2020, 31, 1074-1083.	1.4	1
40	BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report. Journal of Translational Medicine, 2015, 13, P8.	4.4	0
41	Radioembolization (SIRT) as a consolidation treatment in colorectal liver metastases after first line chemotherapy Journal of Clinical Oncology, 2016, 34, e15007-e15007.	1.6	0
42	A combined genomic and immune profile in patients with head and neck squamous cell carcinoma treated with immunotherapy: A pilot study Journal of Clinical Oncology, 2020, 38, e18506-e18506.	1.6	0
43	The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial Journal of Clinical Oncology, 2020, 38, e18508-e18508.	1.6	0